Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell replacement therapies for serious medical conditions. Its lead product candidate is OpRegen, an allogeneic retinal pigment epithelium cell therapy currently in Phase 2a clinical trials for age-related macular degeneration. Another key candidate is OPC1, an allogeneic oligodendrocyte progenitor cell therapy in Phase 1/2a trials for cervical spinal cord injuries. The company also has preclinical programs including ReSonance (ANP1) for sensorineural hearing loss, PNC1 for vision loss due to photoreceptor damage, and RND1 for an undisclosed indication. Additionally, it is developing ILT1 for Type 1 diabetes and LCT-CON for various disorders. Lineage operates in the United States and internationally.

Lineage Cell Therapeutics, Inc. is listed on the NYSE American exchange under the ticker symbol LCTX. The company's financial reporting and stock trading are conducted in US Dollars (USD). As a US-based company, its shares are traded in the primary currency of the United States, making it accessible to investors through US brokerage accounts. The NYSE American is a US equities exchange known for listing smaller-cap and growth-oriented companies, which aligns with Lineage's profile as a clinical-stage biotechnology firm.

Lineage Cell Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative cell replacement therapies that aim to treat or potentially cure serious medical conditions. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight. Lineage's work in cell therapy places it at the forefront of regenerative medicine, targeting areas such as ophthalmology, neurology, and metabolic disorders. The company's clinical-stage status means it has not yet commercialized any products, and its value is largely tied to the success of its ongoing trials and preclinical programs.

Lineage Cell Therapeutics is headquartered in the United States and serves both domestic and international markets. The company's description indicates it operates in the United States and internationally, though specific headquarters location is not provided in the data. As a clinical-stage biotechnology firm, its primary focus is on research and development rather than commercial sales. The company's therapies are being developed for global patient populations, with clinical trials conducted in multiple countries. Its collaboration with William Demant Invest for ReSonance (ANP1) and strategic partnership with Factor Bioscience Inc. for genetic engineering further highlight its international reach and collaborative approach to advancing its pipeline.

Lineage Cell Therapeutics focuses on several therapeutic areas including ophthalmology, neurology, metabolic disorders, and oncology. Its pipeline includes OpRegen for age-related macular degeneration (ophthalmology), OPC1 for spinal cord injury (neurology), ReSonance (ANP1) for hearing loss, PNC1 for vision loss, ILT1 for Type 1 diabetes (metabolic), and RND1 for an undisclosed indication. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1), which targets sensorineural hearing loss. Additionally, it has a strategic collaboration with Factor Bioscience Inc. to develop genetically engineered cell therapies. These partnerships help advance its preclinical programs and leverage external expertise in cell engineering and auditory research.